Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9766030 | 0.95 | SIGMAR1 (0.68) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL9766037 | 0.89 | SIGMAR1 (0.68) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| Hydrochloric Acid SCHEMBL9766004 | 0.88 | SIGMAR1 (0.67) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL9766108 | 0.84 | SIGMAR1 (0.61) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL10435258 | 0.83 | SIGMAR1 (0.56) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| Bmy-14802 SCHEMBL467229 | 0.80 | SIGMAR1 (1.00) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| Bmy-14802 SCHEMBL8457738 | 0.80 | SIGMAR1 (1.00) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL9765977 | 0.80 | SIGMAR1 (1.00) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| Bmy-14802 SCHEMBL466842 | 0.79 | SIGMAR1 (0.97) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| Bmy-14802 SCHEMBL10843594 | 0.79 | SIGMAR1 (0.97) | SIGMAR1KDM4ECYP1A2GAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | claimed |
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | disclosed |